Progress of bispecific antibodies in the field of lung cancer / 肿瘤研究与临床

ABSTRACT

Bispecific antibodies (BsAb) are special antibodies that can bind to two different antigenic epitopes at the same time, and their diverse forms provide the basis for different effects. In 2021, amivanamab was approved to treat metastatic or surgically unresectable non-small cell lung cancer patients with epidermal growth factor receptor (EGFR) 20 exon insertion mutation who experience tumor progression during or after platinum doublet chemotherapy. BsAb has made great progress in the treatment of solid tumors, especially lung cancer. This article reviews the structural form, mechanism and research progress of BsAb in the field of lung cancer.